Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 176

Sort by

Sort Order Select

Journal Articles

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Blood blood.2025030816.

https://doi.org/10.1182/blood.2025030816

Published: 2025

Includes: Supplemental data

Journal Articles

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Blood (2025) 146 (20): 2443–2456.

https://doi.org/10.1182/blood.2024027822

Published: 2025

Includes: Supplemental data

Journal Articles

Dynamic rRNA Methylation Regulates Translation in the Hematopoietic System and is Essential for Stem Cell Fitness

Blood blood.2024028300.

https://doi.org/10.1182/blood.2024028300

Published: 2025

Includes: Supplemental data

Journal Articles

Prospective clinical validation of MAC-scoring as an affordable, real-time biomarker for HMA/venetoclax response in AML

Simon Renders, Alexander Waclawiczek, Ricarda Schwab, Julia Unglaub, Aino-Maija Leppä, Stefan Klein, Tim Sauer, Carsten Müller-Tidow, Michael Hundemer, Andreas Trumpp

Blood (2025) 146 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2025-3493

Published: 2025

Journal Articles

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Julius Michel, Jan Frenking, Anna Metzler, Erin Meermeier, Antonia Schach, Vera Thiel, Tim Wagner, Niklas Kehl, Stefanie Huhn, Alexander Brobeil, Carsten Müller-Tidow, P. Leif Bergsagel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, Marta Chesi, Marc Raab, Niels Weinhold, Mirco Friedrich

Blood (2025) 146 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2025-3951

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Blood (2025) 146 (Supplement 1): 5298.

https://doi.org/10.1182/blood-2025-5298

Published: 2025

Journal Articles

Inflammation conjoins differentiation and resistance in AML

Maike Janssen, Carsten Müller-Tidow

Blood (2025) 145 (21): 2405–2407.

https://doi.org/10.1182/blood.2025028651

Published: 2025

Journal Articles

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Blood (2025) 145 (16): 1780–1787.

https://doi.org/10.1182/blood.2024027342

Published: 2025

Includes: Supplemental data

Journal Articles

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

David N. Sedloev, Qian Chen, Julia M. Unglaub, Anita Schmitt, Carsten Müller-Tidow, Michael Schmitt, Tim Sauer

Blood (2024) 144 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2024-210286

Published: 2024

Journal Articles

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Jan H. Frenking, Christine Riedhammer, David N. Sedloev, Valentine Landrin, Mirco Julian Friedrich, Niels Weinhold, Martin K. Kortüm, Carsten Müller-Tidow, Hermann Einsele, Sandra Sauer, Leo Rasche, Marc S. Raab

Blood (2024) 144 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2024-210021

Published: 2024

Journal Articles

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Anne Kathrin Merbach, Christian Rohde, Sergi Beneyto-Calabuig, Patrick Stelmach, Aino-Maija Leppä, Alexander Waclawiczek, Simon Renders, Michelle Lotze, Lars Velten, Andreas Trumpp, Tim Sauer, Rabia Shahswar, Michael Heuser, Carsten Müller-Tidow, Maike Janssen

Blood (2024) 144 (Supplement 1): 5744.

https://doi.org/10.1182/blood-2024-209706

Published: 2024

Journal Articles

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Blood (2024) 144 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2024-209953

Published: 2024

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 708.

https://doi.org/10.1182/blood-2024-198638

Published: 2024

Journal Articles

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2024-198861

Published: 2024

Journal Articles

Tumor Reactive T Cells Drive Clinical Responses to Multiple Myeloma

Tim Robin Wagner, Niklas Kehl, Simon Steiger, Tamara Boschert, Michael Kilian, Kane A Foster, Hartmut Goldschmidt, Niels Weinhold, Steven A. Carr, Kwee Yong, Carsten Müller-Tidow, Karsten Rippe, Marc S. Raab, Michael Platten, Stefan B Eichmüller, Mirco Julian Friedrich

Blood (2024) 144 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2024-210272

Published: 2024

Journal Articles

Specific U6 Small Nucleolar RNAs Are Present on the Surface of Primary AML Specimens and Are Accompanied By Short Fragments of Longer RNAs

Josephine Jagd Brysting, Christian Rohde, Laura Villacorta, Vladimir Benes, Simon Renders, Judith Zaugg, Carsten Müller-Tidow

Blood (2024) 144 (Supplement 1): 1339.

https://doi.org/10.1182/blood-2024-208198

Published: 2024

Journal Articles

Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A R882 - Mutant Hematopoietic Stem Cells

Patrick Stelmach, Dominik Vonficht, Anne Kathrin Merbach, Dawn S Lin, Sergi Beneyto-Calabuig, Marina Scheller, Aino-Maija Leppä, Florian Grünschläger, George S Vassiliou, Simon Haas, Lars Velten, Carsten Müller-Tidow, Andreas Trumpp

Blood (2024) 144 (Supplement 1): 1292.

https://doi.org/10.1182/blood-2024-203041

Published: 2024

Journal Articles

Endothelial Dysfunction in Hematological Patients: Sublingual Microscopy, Hyperspectral Imaging, and Serum Endothelial Markers

Laura Simons, Muath Qadoura, Jule Buhl, Franziska Sunderer, Felix Korell, Ignatios Ikonomidis, Maximilian Dietrich, Silvia Seidlitz, Hans Vink, Lena Maier-Hein, Richard F. Schlenk, Carsten Müller-Tidow, Peter Dreger, Thomas Luft

Blood (2024) 144 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2024-205216

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Dynamic rRNA Methylation Regulates Translation in the Hematopoietic System and is Essential for Stem Cell Fitness

Prospective clinical validation of MAC-scoring as an affordable, real-time biomarker for HMA/venetoclax response in AML

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Inflammation conjoins differentiation and resistance in AML

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Tumor Reactive T Cells Drive Clinical Responses to Multiple Myeloma

Specific U6 Small Nucleolar RNAs Are Present on the Surface of Primary AML Specimens and Are Accompanied By Short Fragments of Longer RNAs

Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A R882 - Mutant Hematopoietic Stem Cells

Endothelial Dysfunction in Hematological Patients: Sublingual Microscopy, Hyperspectral Imaging, and Serum Endothelial Markers

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only